JBC Connect with Cosmo for Collagen Detection

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M203885200 on August 20, 2002

J. Biol. Chem., Vol. 277, Issue 43, 40594-40601, October 25, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/43/40594    most recent
M203885200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, O. S.
Right arrow Articles by Jou, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, O. S.
Right arrow Articles by Jou, I.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

JAK-STAT Signaling Mediates Gangliosides-induced Inflammatory Responses in Brain Microglial Cells*

Ohn Soon KimDagger, Eun Jung ParkDagger, Eun-hye Joe, and Ilo Jou§

From the Department of Pharmacology, School of Medicine, Ajou University, Suwon 442-721, Korea

Received for publication, April 22, 2002, and in revised form, July 19, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Neuronal cell membranes are particularly rich in gangliosides, which play important roles in brain physiology and pathology. Previously, we reported that gangliosides could act as microglial activators and are thus likely to participate in many neuronal diseases. In the present study we provide evidence that JAK-STAT inflammatory signaling mediates gangliosides-stimulated microglial activation. Both in rat primary microglia and murine BV2 microglial cells, gangliosides stimulated nuclear factor binding to GAS/ISRE elements, which are known to be STAT-binding sites. Consistent with this, gangliosides rapidly activated JAK1 and JAK2 and induced phosphorylation of STAT1 and STAT3. In addition, gangliosides increased transcription of the inflammation-associated genes inducible nitric-oxide syn- thase, ICAM-1, and MCP-1, which are reported to contain STAT-binding elements in their promoter regions. AG490, a JAK inhibitor, reduced induction of these genes, nuclear factor binding activity, and activation of STAT1 and -3 in gangliosides-treated microglia. AG490 also inhibited gangliosides-induced release of nitric oxide, an inflammation hallmark. Furthermore, AG490 markedly reduced activation of ERK1/2 MAPK, indicating that ERKs act downstream of JAK-STAT signaling during microglial activation. However, AG490 did not affect activation of p38 MAPK. We also report that the sialic acid residues present on gangliosides may be one of the essential components in activation of JAK-STAT signaling. The present study indicates that JAK-STAT signaling is an early event in gangliosides-induced brain inflammatory responses.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Gangliosides are sialic acid-containing glycosphingolipids that are constituents of mammalian cell membranes. Gangliosides are particularly abundant in neuronal cell membranes and participate in various cellular events of the nervous system (1, 2). The major types of gangliosides in the brain are GM1, GD1a, GD1b, GT1b, and GQ1b, which differ in their profiles of sialic acid residues and carbohydrate moieties. Several lines of evidence point to the importance of the brain-derived gangliosides in immune responses and the pathogenesis of brain disease. There are reports that brain injury can cause release of gangliosides from damaged neuronal cells into the extracellular space, which may lead to pathophysiological conditions (3-5). Gangliosides have also been reported to interact with Abeta , suggesting they play a role in Abeta toxicity as well as in the deposition of Abeta into senile plaques associated with Alzheimer's disease (6-9). In addition, gangliosides regulate the production of various inflammatory mediators, such as cytokines and inducible nitric-oxide synthase (iNOS)1 (10, 11). Despite the evidence of a role for gangliosides in brain pathology, there appears to be little known about how gangliosides act.

Janus kinase-signal transducers and activators of transcription (JAK-STAT) signaling pathways have been reported to be involved not only in the immune response of numerous cytokines but also in the actions of primarily non-immune mediators such as growth factors and hormones. Specific subtypes of JAK and STAT molecules are activated by different signals, resulting in specificity of response (12, 13). The binding of ligand to its receptor induces assembly of an active receptor complex and consequent phosphorylation of the receptor-associated JAKs (JAK1, JAK2, JAK3, and TYK2). Phosphorylated JAKs lead to the activation of neighboring JAKs, receptor subunits, and several other substrates. Phosphorylation of JAKs provides the docking sites for STATs, which in turn become phosphorylated on tyrosine and serine residues; the phosphorylation of both amino acid species is required for full STAT activity. Phosphorylated STATs are released from the receptor complex and form dimers. These dimers translocate to the nucleus where they directly bind to the promoter region of specific target genes, thus regulating transcription of these genes, many of which are involved in immune responses (13-16).

Microglia are the major immune effector cells in the brain, and microglial activation is an early event in central nervous system inflammation (17, 18). Previously, we demonstrated that gangliosides could activate microglia, inducing release of inflammatory mediators such as tumor necrosis factor-alpha and nitric oxide (NO) (10, 19). Here we show that the molecular mechanisms underlying this gangliosides-induced activation of microglia include triggering of the JAK-STAT signaling pathway.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Reagents-- Bovine brain gangliosides mixture, GM1 and GD1a, was purchased from Matreya (Pleasant Gap, PA). Asialoganglioside GM1 was from Sigma. Rat IFN-gamma , alpha -cyano-(3,4-dihydroxy)-N-benzylcinnamide (AG490), and PD98059 were from Calbiochem. Anthrobacter ureafaciens neuraminidase was from Sigma. Dulbecco's modified Eagle's medium and minimal essential medium were from Invitrogen. Antibodies against STAT1, Tyr-701-phosphorylated STAT1, Ser-727-phosphorylated STAT1, and Tyr-705-phosphorylated STAT3 were from Cell Signaling Technology (Beverly, MA). Antibodies against phosphorylated ERK, ERK, and phosphorylated p38 were from Calbiochem. Antibodies against phosphorylated JAK1 and -2 were from Affinity Bioreagents (Denver, CO).

Cell Culture-- Primary microglia were cultured from the cerebral cortices of 1-3-day-old Sprague-Dawley rats as described previously (10). Briefly, the cortices were triturated into single cells in minimal essential medium containing 10% fetal bovine serum (HyClone, Logan, UT) and plated in 75-cm2 T-flasks (0.5 hemisphere/flask) for 2-3 weeks. Microglia were then detached from the flasks by mild shaking and filtered through a nylon mesh to remove astrocytes. Cells were plated in 6-well plates (7 × 104 cells/well), 60-mm dishes (5 × 105 cells/dish), or 100-mm dishes (106 cells/well). One hour later, the cells were washed to remove unattached cells before being used in experiments. BV2 immortalized murine microglia cells were from Dr. E. J. Choi. The BV2 cell line was grown in Dulbecco's modified Eagle's medium and supplemented with 5% fetal bovine serum. Cells were serum-starved overnight before treatment with gangliosides.

Electrophoretic Mobility Shift Assay (EMSA)-- Cells were harvested and suspended in 9 times packaged cell volume of a hypotonic solution (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride) including 0.5% Nonidet P-40. Cells were centrifuged at 500 × g for 10 min at 4 °C, and the pellet (nuclear fraction) was saved. The nuclear fractions were resuspended in a buffer containing 20 mM HEPES, pH 7.9, 20% glycerol, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride, incubated on ice for 60 min with occasional gentle shaking, and centrifuged at 12,000 × g for 20 min. The crude nuclear proteins in the supernatant were collected and stored at -70 °C for EMSA. EMSA was performed for 30 min on ice in a volume of 20 µl, containing 4 µg of nuclear protein extract in a reaction buffer containing 8.5 mM EDTA, 8.5 mM EGTA, 8% glycerol, 0.1 mM ZnSO4, 50 µg/ml poly(dI-dC), 1 mM dithiothreitol, 0.3 mg/ml bovine serum albumin, 6 mM MgCl2, and gamma -32P-radiolabeled oligonucleotide probe (3 × 104 cpm), with or without 20-50-fold excess unlabeled probe. In supershift experiments, protein extracts were incubated with 0.2-0.5 µg of STAT1 and STAT3 antibodies (Santa Cruz Biotechnology) for 30 min prior to the addition of 32P-labeled probe. DNA-protein complexes were separated on 6% polyacrylamide gels in Tris/glycine buffer. The dried gels were exposed to x-ray film. The following double-stranded oligonucleotide was used in these studies: GAS/ISRE, 5'-AAGTACTTTCAGTTTCATATTACTCTA-3', 27 bp (Santa Cruz Biotechnology, Inc., sc-2537). 5'-End-labeled probes were prepared with 40 µCi of [gamma -32P]ATP using T4 polynucleotide kinase (Promega) and were purified on Quick Spin Columns Sephadex G-25 (Roche Molecular Biochemicals).

Reverse Transcription-PCR-- Total RNA was extracted using RNAzol B (Tel-Test Inc.) and cDNA was prepared using reverse transcriptase that originated from avian myeloblastosis virus (Takara), according to the manufacturer's instructions. PCR was performed with 30 cycles of sequential reactions as follows: 94 °C for 30 s, 55 °C for 30 s, and 72 °C for 30 s. Oligonucleotide primers were purchased from Bioneer (Seoul, Korea). The sequences of PCR primers are as follows: (reverse) 5'-GCAGAATGTGACCATCATGG-3' and (forward) 5'-ACAACCTTGGTGTTGAAGGC-3' for iNOS; (reverse) 5'-AAGGCCGCAGAGAGCAAAAGAAGC-3' and (forward) 5'-CTGGAGAGCACAAACAGCAGAG-3' for ICAM-1; (reverse) 5'-ATGCAGGTCTCTGTCACGCT-3' and (forward) 5'-CTAGTTCTCTGTCATACTGG-3' for MCP-1; (reverse) 5'-AGATCCACAACGGATACATT-3' and (forward) 5'-TCCCTCAAGATTGTCAGCAA-3' for glyceraldehyde-3-phosphate dehydrogenase.

Western Blot Analysis-- Cells were washed twice with cold phosphate-buffered saline and then lysed in ice-cold modified RIPA buffer (50 mM Tris-HCl, pH 7.4, 1% Nonidet P-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM Na3VO4, and 1 mM NaF) containing protease inhibitors (2 mM phenylmethylsulfonyl fluoride, 100 µg/ml leupeptin, 10 µg/ml pepstatin, 1 µg/ml aprotinin, and 2 mM EDTA). The lysates were centrifuged for 10 min at 12,000 × g at 4 °C, and the supernatant was collected. Proteins were separated by SDS-PAGE and transferred to nitrocellulose membrane. The membrane was incubated with primary antibodies and peroxidase-conjugated secondary antibodies (Vector Laboratories, Burlingame, CA) and then visualized using an enhanced chemiluminescence system (Sigma).

Determination of NO Release-- Media nitrite concentration was measured as an indication of NO release. Following the indicated cell incubations, 50 µl of culture medium was removed and mixed with an equal volume of Griess reagent (0.1% naphthylethylenediamine, 1% sulfanilamide, 2.5% H3PO4), and absorbance of the mixture at 540 nm was measured.

Enzymatic Digestion of Sialic Acid-- Neuraminidase derived from A. ureafaciens was used for cleaving sialic acids residues from gangliosides. Gangliosides were dissolved in 10 mM sodium acetate buffer, pH 5.0, containing 1 µg of sodium cholate per µl and were incubated with A. ureafaciens neuraminidase (Sigma) at 37 °C for 2 h.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Gangliosides Induce Nuclear Factor Binding to GAS/ISRE Elements-- Functional GAS/ISRE elements are found in the promoter regions of several inflammation-related genes, such as iNOS, and these elements are known to bind the phosphorylated STAT dimer (15, 20-22). In an attempt to explore the molecular mechanism of gangliosides on microglial activation, we investigated whether STATs could be involved in gangliosides-induced activation of microglia. We first examined the transcript level of iNOS in gangliosides-treated rat primary microglia. Gangliosides markedly induced iNOS mRNA within 1 h, suggesting that gangliosides directly regulate NO production at the level of transcription (Fig. 1A). Our assumption was subsequently evaluated by EMSA using a gamma -32P-labeled consensus GAS/ISRE oligonucleotides probe. After the cells were treated with 50 µg/ml brain-derived ganglioside mixture for the indicated times, nuclear extracts were prepared and then analyzed by EMSA. The specific binding complex was detected in nuclear extracts from gangliosides-treated rat primary and murine BV2 microglia (Fig. 1, A and B). Time course analysis showed that gangliosides rapidly induced the nuclear factor binding within 5 min and that the binding activity was decreased to basal levels after 30 min in both microglial cell types (Fig. 1B and data not shown). The specificity of the shifted bands was confirmed by competition assay using excess amounts of unlabeled oligonucleotides (Fig. 1B). In addition, gel shift assay showed that the binding complex was diminished by addition of anti-STAT1 and anti-STAT3, indicating that both STAT1 and STAT3 are constituents of the nuclear factor binding complex (Fig. 1C). These results show that functional GAS/ISRE elements may be involved in gangliosides-induced activation of microglia.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 1.   Gangliosides stimulate iNOS transcription and nuclear factor binding to GAS/ISRE elements. A, transcript level of iNOS and nuclear factor binding to GAS/ISRE element in gangliosides-treated rat primary microglia. Rat primary microglial cells were treated with or without 50 µg/ml brain gangliosides mixture (Gmix) for 1 h, after which total RNA was isolated, and levels of iNOS mRNA were measured using an RT-PCR-based assay (left). Cells were treated with Gmix for 5 min, after which nuclear extracts were prepared and assayed for the amount of binding activity to GAS/ISRE oligonucleotides using EMSA (right). GAPDH, glyceraldehyde-3-phosphate dehydrogenase. B, time course analysis of nuclear factor binding activity in mouse BV2 microglial cells. BV2 cells were treated with 50 µg/ml Gmix for the indicated periods. Nuclear extracts were prepared, and binding activity to GAS/ISRE oligonucleotides was determined by EMSA. Data are representative of four independent experiments. C, gel shift assay using anti-STAT1 and anti-STAT3 in BV2 cells. After cells were treated with 50 µg/ml Gmix for 5 min, gel shift assays were performed as described above with the exception that nuclear extracts were incubated with 0.2-0.5 µg of STAT1 and STAT3 antibodies for 30 min prior to the addition of 32P-labeled probe. *, inset is a short-exposed autograph of the upper band (dotted box).

Gangliosides Induce the Phosphorylation of STAT1 and STAT3-- Essential roles for STAT signaling in brain inflammatory response have emerged (20, 23, 24). Because gangliosides rapidly induced the GAS/ISRE-nuclear factor binding, we examined whether gangliosides indeed caused phosphorylation of STAT proteins. Primary microglial cells were stimulated with 50 µg/ml gangliosides for the indicated times, and the levels of phosphorylated STAT1 were determined by Western blot analysis using antibodies against Tyr-701-STAT1 and Ser-727-STAT1. Both phosphorylations of STAT1 occurred within 1 min of gangliosides addition and then decreased at 30 min (Fig. 2A). Similar patterns of phosphorylation were observed in lysates from murine BV2 microglial cells, where incubation of cells with gangliosides resulted in STAT1 phosphorylation on tyrosine and serine residues, with phosphorylation levels returning to basal at 30 min (Fig. 2B). In addition to phosphorylation of STAT1, we detected gangliosides-induced phosphorylation of STAT3 in both microglial cell types. The pattern of STAT3 tyrosine phosphorylation appeared similar to that of STAT1 phosphorylation (Fig. 2, A and B). The Western blotting data show that gangliosides trigger rapid phosphorylation of STAT1 and STAT3, suggesting their involvement in gangliosides-induced microglial activation. The phosphorylation patterns of both STAT1 and STAT3 determined by Western blotting correlate with the binding activity results from EMSA.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 2.   Gangliosides induce the phosphorylation of STAT1 and STAT3 in microglial cells. Rat primary microglial cells (A) and mouse BV2 microglial cells (B) were serum-starved for 12 h and then stimulated with 50 µg/ml Gmix for the indicated times. Cell lysates were separated by 10% SDS-PAGE and Western blots probed with anti-pSTAT1 (Tyr-701), anti-pSTAT1 (Ser-727), or pSTAT3 (Tyr-705). The membrane was then stripped and analyzed with anti-STAT1 antibody to determine loading. Data are representative of four independent experiments.

Gangliosides Induce Phosphorylation and Activation of JAK1 and JAK2-- Phosphorylation of STATs depends on the activation of JAKs (25). JAKs both functionally and physically associate with cytokine signaling. In particular, activation of JAK1 and JAK2 provides a molecular explanation for cellular actions of a broad range of cytokines (26, 27). Thus, we investigated whether JAK1 and JAK2 could be involved in gangliosides-induced STAT phosphorylation. Primary rat microglial cells were stimulated with 50 µg/ml gangliosides for the indicated times, and cell lysates were Western blotted using antibodies directed against phosphorylated JAK1 and JAK2. The data presented in Fig. 3A show that following addition of gangliosides to cells, phosphorylation of both JAK1 and JAK2 occurred within 5 min, after which phosphorylation levels returned to basal levels by 30 min. The involvement of JAK signaling in gangliosides-induced microglial activation was also shown using a second, independent approach. The pharmacological agent AG490 is known to inhibit the phosphorylation of both JAK1 and JAK2 (20). We found that pretreatment of rat primary microglial cells with AG490 effectively reduced gangliosides-induced phosphorylation of STAT1 and STAT3 (Fig. 3B). In addition, AG490 inhibited the nuclear factor binding to GAS/ISRE nucleotides in gangliosides-treated microglial cells (Fig. 3C). These results indicate that gangliosides induce phosphorylation and activation of STAT1 and STAT3 through phosphorylation and activation of JAK1 and JAK2.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 3.   Gangliosides stimulate phosphorylation of JAK1 and JAK2 in rat primary microglial cells. A, phosphorylated levels of JAK1 and -2 in gangliosides-treated rat primary microglial cells. Cells were serum-starved for 12 h and then stimulated with 50 µg/ml Gmix for 5 min. The phosphorylation of JAK1 and JAK2 was determined by Western blot analysis using antibodies specific for phospho-JAK1 or -2. B, inhibition of gangliosides-induced phosphorylation by AG490. Cells were pretreated with 10 µM AG490 for 1 h and then stimulated with 50 µg/ml Gmix for 2 min. Western blots were probed with anti-pSTAT1 (Tyr-701) and pSTAT3 (Tyr-705). The membrane was subsequently stripped and probed with anti-STAT1 and STAT3 antibodies. C, inhibition of nuclear factor binding to GAS/ISRE oligonucleotides by AG490. Cells were pretreated with 10 µM AG490 for 1 h and then stimulated with 50 µg/ml Gmix for 5 min. Nuclear extracts were prepared, and binding activity to GAS/ISRE oligonucleotides was determined by EMSA. *, inset is a short-exposed autograph of the upper band (dotted box).

Gangliosides Stimulate STAT-responsive Inflammatory Gene Expression-- Brain inflammatory responses are coordinated by the production of cytokines, chemokines, and reactive oxygen species (17). The above data indicate that gangliosides-induced microglial activation may be mediated, at least in part, by JAK-STAT-dependent transcriptional responses. Therefore, we examined the transcript level of genes that have been reported previously (29, 30) to have functional GAS elements and act as mediators of inflammation, namely monocyte chemoattractant protein-1 (MCP-1) and intercellular adhesion molecule-1 (ICAM-1). Rat primary microglial cells and BV2 cells were stimulated with 50 µg/ml gangliosides for 3 h, and total RNA was extracted for RT-PCR analysis. Addition of gangliosides rapidly increased the mRNA levels of both MCP-1 and ICAM-1, as did IFN-gamma , which was included as a positive control (Fig. 4A). Pretreatment with AG490 significantly inhibited gangliosides-induced transcription of both genes (Fig. 4B). These findings demonstrate that gangliosides trigger STAT-dependent transcriptional activation of inflammatory genes in microglia.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 4.   Gangliosides stimulate transcription of STAT-responsive inflammatory genes in microglial cells. AG490 suppresses this transcription. A, gangliosides-induced transcription of MCP-1 and ICAM-1 in rat primary microglial cells. Cells were treated for 3 h with 50 µg/ml Gmix or 10 units/ml IFN-gamma . Total RNA was isolated and analyzed for levels of MCP-1 and ICAM-1 mRNA using an RT-PCR-based assay. The transcription of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was measured for normalization. B, the effect of AG490 on gangliosides-induced transcription. Cells were pretreated with 10 µM AG490 for 1 h and then stimulated with 50 µg/ml Gmix for 3 h. mRNA expression of MCP-1 and ICAM-1 was detected using an RT-PCR-based assay. Data are representative of three independent experiments.

AG490 Reduces Gangliosides-induced Release of NO-- NO is known as an important physiological signaling molecule in the brain. Aberrant iNOS expression and excessive NO production are observed in various pathophysiological conditions (31). Previously, we showed (10) that gangliosides-induced microglial activation was accompanied by induction of NO release. Thus, we tested whether gangliosides induced NO release via JAK-STAT signaling. First, we examined the effect of JAK inhibition on gangliosides-induced transcription of iNOS in rat primary microglial cells. RT-PCR analysis showed that the inhibitor AG490 reduced mRNA levels of iNOS (Fig. 5). Second, we investigated the effect of AG490 on NO release. In these studies, the ERK inhibitor, PD98059, was also used since we have shown previously (10) that it reduced gangliosides-induced NO release. In the presence of AG490, microglial cells were treated with 50 µg/ml gangliosides for 48 h, and the amount of NO produced was determined by measuring the amount of nitrite converted from NO in the media. AG490 significantly reduced gangliosides-enhanced NO release, as did PD98059 (Fig. 5). Compared with cells treated with gangliosides alone, NO release was reduced to 38.6 ± 4.3 and 25.2 ± 14% in cells co-treated with PD98059 and AG490, respectively. These results are consistent with the results shown in Figs. 3 and 4. The findings indicate that JAK-STAT signaling is required for NO release and provide evidence of the critical functional involvement of JAK-STAT signaling in gangliosides-induced microglial activation.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 5.   AG490 reduces gangliosides-stimulated NO in rat primary microglial cells. A, inhibition of gangliosides-induced iNOS transcription by AG490. Cells were pretreated with 10 µM AG490 for 1 h and then stimulated with 50 µg/ml Gmix for 3 h. mRNA expression of iNOS was detected by RT-PCR analysis. B, inhibition of gangliosides-induced NO release by AG490. Cells were treated with 50 µg/ml Gmix for 48 h in the presence or absence of AG490 or PD98059. The amount of NO was determined by measuring the amount of nitrite in the media, as described under "Experimental Procedures." GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

ERK Activity Appears to be Regulated by JAK Activation-- There are several reports (32, 33) showing that the transcriptional activity of STATs is regulated through mitogen-activated protein kinases (MAPKs). MAPKs are considered as common intracellular signaling molecules involved in microglial activation. Previous reports by others and us (10, 34) showed that gangliosides induced activation of MAPKs in microglia. In the present study, we used pharmacological inhibitors to examine possible cross-talk between the JAK-STAT and MAPKs signaling pathways. When primary rat microglial cells were pretreated for 2 h with the JAK inhibitor AG490, gangliosides-induced activation of ERK1/2 was significantly reduced compared with controls with no AG490 (Fig. 6). In contrast, no significant suppression of p38 was observed under this condition. However, in the presence of PD98059, an ERK inhibitor, not only ERK but also p38 activation was completely inhibited. These results indicate that gangliosides-stimulated JAK activation leads to activation of ERK in microglial cells. These pharmacological studies also indicate that gangliosides-stimulated activation of p38 may not be due to activation of ERK by JAK.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 6.   Activation of ERK1/2 follows JAK-STAT activation in gangliosides-treated primary microglial cells. Primary microglial cells were pretreated with AG490 or PD98059 for 1 h and then treated with 50 µg/ml Gmix for 30 min. Cell lysates were separated by 10% SDS-PAGE and Western blots probed with anti-phospho-ERK and anti-phospho p38, respectively. The membrane was then stripped and probed with anti-ERK antibody. At least four experiments were independently performed, and representative data are shown in this figure.

Sialic Acid Residues Are Important for Gangliosides-induced Phosphorylation of STAT-- The major types of gangliosides in brain are GM1, GD1a, GD1b, GT1b, and GQ1b. These gangliosides differ with respect to the number and position of sialic acid residues attached to the carbohydrates (35). The approximate percentages of each ganglioside present in the brain gangliosides mixture used in the current study are 18% GM1, 55% GD1a, 15% GD1b, 10% GT1b, and 2% others. To address whether the structural diversity of gangliosides affected activation of STAT, we compared the effect of GM1, which has one molecule of sialic acid, with GD1a, which has two molecules of sialic acid, on phosphorylation of STAT1. Primary microglial cells were treated with GM1 or GD1a for 2 min, and levels of phosphorylated STAT1 were determined by Western blot analysis using antibodies against Tyr-701-STAT1. The data in Fig. 7A show both GM1 and GD1a stimulated phosphorylation of STAT1 within 2 min. The level of STAT1 phosphorylation stimulated by either GM1 or GD1a was similar to that caused by the gangliosides mixture, suggesting that the number of sialic acid residues per ganglioside molecule has little effect on the phosphorylation of STAT1 in microglial cells (Fig. 7A). Because sialic acid residues are characteristic of gangliosides, we examined whether sialic acid residues were important for gangliosides-stimulated STAT phosphorylation. Gangliosides were preincubated with either 550 or 1000 units/ml A. ureafaciens neuraminidase, which is known to release sialic acid attached to an internal galactose in any gangliosides including GM1 (36, 37). Primary microglia cells were stimulated with gangliosides or neuraminidase-treated gangliosides (desialylated gangliosides) for 2 min, and levels of phosphorylated STAT1 were determined by Western blot analysis. The data presented in Fig. 7B show a dose-dependent inhibitory effect of neuraminidase treatment on phosphorylation of STAT1, indicating that sialic acid residues are required for stimulation of JAK-STAT signaling. To rule out the possibility that these reductions are due to contaminating sialic acid or neuraminidase, we compared the effect of GM1 and asialo-GM1(Sigma) on phosphorylation of STAT and transcription of STAT-responsive genes. Consistent with Fig. 7, not only the phosphorylation of STAT1 and STAT3 but also the transcriptions of iNOS, MCP-1, and ICAM-1 were not induced in asialo-GM1-treated primary microglial cells (Fig. 8). Taken together, these results suggest that the presence of sialic acid residues is important for gangliosides-stimulated JAK-STAT signaling, although the number of sialic residues per ganglioside molecule may not influence phosphorylation.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 7.   The sialic acid residue of gangliosides is necessary for activation of JAK-STAT signaling. A, effect of GM1 and GD1a on phosphorylation of STAT1. Primary microglial cells were treated with 20 µg/ml GM1 or GD1a for 2 min. Cell lysates were subjected to Western blot analysis, and levels of phosphorylated STAT1 were determined using anti-pSTAT1 (Tyr-701). B, effects of neuraminidase on gangliosides-induced phosphorylation of STAT1 in primary microglial cells. To remove the sialic acid residue, gangliosides were preincubated with 550 or 1000 units/ml A. ureafaciens neuraminidase as described under "Experimental Procedures." Cells were treated with the indicated gangliosides or the desialylated gangliosides for 2 min, after which cell lysates were prepared, separated by 10% SDS-PAGE, Western blotted, and probed using anti-pSTAT1 (Tyr-701). The membrane was then stripped and probed with anti-STAT1 antibody.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 8.   Asialo-GM1 does not activate the JAK-STAT signaling in primary microglial cells. A, effect of GM1 and asialo-GM1 on phosphorylation of STAT. Primary microglial cells were treated with 20 µg/ml of GM1 or asialo-GM1 for 2 min. Cell lysates were subjected to Western blot analysis, and levels of phosphorylated STAT were determined using anti-pSTAT1 and anti-pSTAT3. Con, control. B, effect of GM1 and asialo-GM1 on STAT-responsive transcription. Total RNA was isolated and analyzed for levels of iNOS, MCP-1, and ICAM-1 mRNA using an RT-PCR-based assay.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Increasing evidence indicates that gangliosides act not only as mediators for cellular interactions but also as modulators of signal transduction in a variety of cellular events. These functions appear to occur simultaneously and influence each other (38). Identification of the precise mechanisms underlying how gangliosides regulate cellular responses has been the subject of many investigations, but it appears there is still much that is unknown (11, 34, 39). In this study, we reveal that gangliosides directly induce the activation of JAK-STAT signaling, a key pathway in inflammation, which leads to the expression of several inflammation-associated genes.

JAK-STAT signaling has been reported to be closely involved in inflammation. Although STAT proteins were discovered during the course of analysis of interferon signaling, recent studies (40-42) have revealed that STAT signaling can account for various cellular responses to a number of cytokines, growth factors, and hormones. IL-4 and IL-13 stimulate enhanced expression of major histocompatibility complex class II, CD23, IL-4Ra chain, and Ig class switching to IgE and IgG via activation of STAT6 (43, 44). The common cytokine receptor gamma -chain, which is shared by receptors for IL-2, -4, -7, -9, and -15, associates with JAK3, thus resulting in STAT-dependent immune responses (45, 46). Prolactin, erythropoietin, and growth hormone are all known to activate JAK2 (47).

The functional association between cytokine signaling and JAK-STAT signaling prompted us to examine the involvement of STATs in gangliosides-induced inflammatory responses. Consistent with a connection between gangliosides and STAT activity, we found that gangliosides treatment of brain microglial cells increased the binding activity of a nuclear factor to a consensus GAS/ISRE element (Fig. 1). It has been reported that STAT1 and -3 are major STAT types that bind GAS and ISRE elements, and that they function to regulate the transcription of numerous genes (21, 24). By using supershift antibodies for STAT1 and STAT3, we determined that they are constituents of nuclear factor binding complex to the GAS/ISRE element in gangliosides-stimulated microglial cells (Fig. 1C). At the present time, we cannot clearly identify the individual bands since all the three bands were reduced by addition of not only anti-STAT1 but also anti-STAT3. However, our EMSA data and Western blotting data convincingly proved the involvement of STAT1 and STAT3 in gangliosides-induced inflammatory responses. Next, we investigated whether gangliosides could induce the phosphorylation of these particular STATs. As expected, phosphorylation of STAT1 and -3 was induced within 1 min and then rapidly decreased to basal levels (Fig. 2). The kinetics of these phosphorylation events were consistent with the timing of binding activity to GAS/ISRE elements. These results show that STAT1 and -3 may directly mediate gangliosides-induced microglial activation. NF-kappa B is also reported to be involved in gangliosides-induced microglial activation, but it is considered to be a pathway common to a range of microglial activators (10). Thus, it may be that early activation of STATs by gangliosides is a specific mechanism underlying gangliosides-induced microglial activation.

Phosphorylation of JAKs leads to their activation, and activated JAKs phosphorylate and hence activate STATs. We examined the effect of gangliosides on JAK1 and JAK2 to determine the cause of STAT1 and STAT3 phosphorylation. We found that both JAK1 and JAK2 were phosphorylated within 1 min of the addition of gangliosides (Fig. 3). Furthermore, AG490, a JAK inhibitor, diminished both gangliosides-enhanced phosphorylation of STATs and nuclear factor binding activity. These data provide strong evidence to indicate that gangliosides activate STATs through activation of JAKs.

In general, inflammatory stimuli induce release of mediators such as cytokines, chemokines and cell adhesion molecules (49). Regulation of mediator release is important for controlling inflammation. We investigated the transcription of inflammation-associated genes that contain functional GAS elements in their promoters. RT-PCR analysis showed that gangliosides enhanced the transcript level of ICAM-1 and MCP-1 within 3 h, whereas pretreatment with AG490 inhibited this increase (Fig. 4). These results provide further evidence for involvement of JAK-STAT inflammatory signaling in gangliosides-induced microglial activation. Moreover, AG490 significantly reduced gangliosides-induced NO release, indicating that NO production was partly dependent on JAK-STAT signaling (Fig. 5). Taken together, these results suggest that inflammatory mediators including MCP-1, ICAM-1, and NO may be induced in response to gangliosides through JAK-STAT signaling.

We next examined other signaling events that may be associated with JAK-STAT activation in gangliosides-treated microglial cells. Having previously observed that ERKs and p38 MAPKs were activated by gangliosides, we investigated whether gangliosides-stimulated JAK-STAT signaling was linked to activation of ERKs and p38 MAPKs. By using pharmacological inhibitors, we found that gangliosides-stimulated activation of JAK resulted in phosphorylation of ERK1/2 (but not p38) (Fig. 6), suggesting cross-talk between JAK and ERK pathways. Interestingly, inhibition of ERK by PD98059 resulted in complete inhibition of p38 activation, indicating cross-talk between different MAP kinase pathways. Because AG490 only partially reduced the phosphorylation of ERK, but PD98059 completely inhibited the activation of ERKs and p38, it is likely that activation of p38 is downstream of ERK activation and that any connection occurs via signaling molecules other than JAK-STATs. The activation profile of signaling molecules seems to depend on stimulators and/or cell types. Furthermore, upstream and downstream signaling molecules may be specifically affected by cross-talk and convergence in a particular environment. For example, Gouni-Berthold et al. (34) recently reported that gangliosides had no effect on phosphorylation of p38 in vascular smooth muscle cells, and that platelet-derived growth factor-BB-induced phosphorylation of p38 was not influenced by PD98059. In contrast, both MAPKs are activated by lipopolysaccharides and gangliosides in primary glial cells (10, 50). In view of the fact that gangliosides-induced activation of JAK-STAT signaling occurs more rapidly than activation of ERKs, and that inhibition of JAK activation reduced ERKs activation, it appears gangliosides-stimulated JAK-STAT signaling regulates ERKs activation in microglial cells. In contrast, p38 activation does not seem to be linked to JAK-STAT signaling, even though it too plays a role in microglial activation.

Gangliosides are amphipathic molecules that belong to a class of anionic glycosphingolipids. They contain sialic acid residues (N-acetylneuraminic acids), linked to the sugar residues of a ceramide oligosaccharide. It has been reported (34, 51) that different types of gangliosides have distinct roles in several cell types. To gain insight into the mechanism underlying JAK-STAT activation by gangliosides, we investigate whether GM1 and GD1a, the major types of gangliosides mixture used in these studies (18 and 55%, respectively), had different effects on STAT activation. Despite containing different numbers of sialic acid residues per molecule, GM1 containing one and GD1a containing two, both gangliosides activated STAT1 to a similar extent, which was similar to the activation caused by the gangliosides mixture. Although the different number of sialic acid residues on a gangliosides appeared to have no influence on STAT phosphorylation, the presence of sialic acid on a gangliosides was critical, since removal of sialic acid by neuraminidase resulted in reduced STAT1 phosphorylation (Fig. 7). These results are further confirmed by experiments to compare activities of GM1 and asialo-GM1. Unlike GM1, asialo-GM1 did not induce phosphorylation of STAT or expression of STAT-responsive genes including iNOS (Fig. 8) Thus, it appears sialic acid residues of gangliosides are important for STAT activation, and one residue per molecule is sufficient. However, we do not exclude the possibility that other moieties of gangliosides also importantly affect JAK-STAT signaling in microglial cells.

It is intriguing, but unresolved, as to how gangliosides stimulate phosphorylation of JAKs. One possibility is that gangliosides act by binding to specific cell surface receptors. However, although galectin-1 and -3 are reported to bind GM1, the specific receptors of gangliosides have not been clearly elucidated (51). Alternatively, gangliosides may act by modulating other signaling molecules. For example, there are reports (52-55) that incorporation of gangliosides into plasma membranes regulates CD4, growth factor receptors, and phospholipase C. It may be that the gangliosides-enriched membrane domains, assigned as lipid rafts, regulate intermolecular associations in the plasma membranes. Many transmembrane receptors are reported to be constitutively or inducibly localized within lipid rafts (36, 56-58). It has been reported that the Src family kinases Rho, FAK, Lyn, and Lck are associated with ganglioside-enriched lipid rafts (56, 39, 59, 60). Interestingly, a recent report (28) showed that JAK1 and JAK2 are exclusively localized in lipid rafts of mouse embryonic fibroblasts. Furthermore, it has been suggested that JAKs interact not only with STATs but also with several other proteins such as Grb2, Shc, Vav, Fyn, and c-Abl (25, 48, 61). Based on these reports and our current findings that JAK-STAT signaling is rapidly activated by gangliosides, it is possible that gangliosides physically and functionally associate with certain signaling molecules in membranes, thereby activating JAKs. In this regard, we are interested in the composition and functional organization of gangliosides in the membrane. Further studies are needed to clarify how gangliosides act to initiate JAK-STAT signaling. These studies will provide important information regarding microglial activation.

In conclusion, our findings suggest that gangliosides rapidly trigger JAK-STAT inflammatory signaling, resulting in brain microglial activation. Our studies indicate that gangliosides-stimulated JAK-STAT signaling mediates several important inflammatory events, including production of NO and transcription of inflammatory mediators. Gangliosides are now emerging as important factors in signaling pathways and neuronal diseases. Our data provide significant new information regarding the molecular mechanisms underlying gangliosides-induced microglial inflammation, and such knowledge will assist in the better understanding of the pathogenesis of brain disease.

    ACKNOWLEDGEMENT

We thank Dr. E. J. Choi (Korea University, Seoul, Korea) for providing BV2 cells.

    FOOTNOTES

* This work was supported by Grant R01-2000-00164 from the Basic Research Program of the KOSEF and by Critical Technology 21[01-J-LF-B-77 Grant from the Korea Ministry of Science and Technology (to I. J.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Both authors contributed equally to this paper.

§ To whom correspondence should be addressed: Dept. of Pharmacology, School of Medicine, Ajou University, Suwon, 442-721, Korea. Tel.: 82-31-219-5061; Fax: 82-31-219-5069; E-mail: jouilo@madang.ajou.ac. kr.

Published, JBC Papers in Press, August 20, 2002, DOI 10.1074/jbc. M203885200

    ABBREVIATIONS

The abbreviations used are: iNOS, inducible nitric-oxide synthase; NO, nitric oxide; JAK-STAT, JAK-STAT, Janus kinase-signal transducers and activators of transcription; ERK, extracellular signal-regulated kinase; MAPKs, mitogen-activated protein kinases; EMSA, electrophoretic mobility shift assay; GAS/ISRE, gamma -interferon-activated sequence/interferon-alpha -stimulated response element; RT, reverse transcription; MCP-1, monocyte chemoattractant protein-1; ICAM-1, intercellular adhesion molecule-1; IFN, interferon; IL, interleukin.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Derry, D. M., and Wolfe, L. S. (1967) Science 158, 1450-1452[Abstract/Free Full Text]
2. Rodden, F. R., Wiegandt, H., and Bauer, B. L. (1991) J. Neurosurg. 74, 606-619[Medline] [Order article via Infotrieve]
3. Michikawa, M., Gong, J., Fan, Q., Sawamura, N., and Yanagisawa, K. (2001) J. Neurosci. 21, 7226-7235[Abstract/Free Full Text]
4. Blennow, K., Davidsson, P., Walin, A., Fredman, P., Gottfries, C. G., Karlsson, I., Mansson, J. E., and Svennerholm, L. (1991) Arch. Neurol. 48, 1032-1035[Abstract]
5. Gisslen, M., Hagberg, L., Norkransn, G., Lekman, A., and Fredman, P. (1997) J. Neurovirol. 3, 148-152[Medline] [Order article via Infotrieve]
6. Yanagisawa, K., Okada, A., Suzuki, N., and Ihara, Y. (1995) Nat. Med. 1, 1062-1066[CrossRef][Medline] [Order article via Infotrieve]
7. Ledesma, M. D., Silva, J. S. D., Cassaerts, K., Delacourte, A., Strooper, B. D., and Dotti, C. G. (2000) EMBO Rep. 6, 530-535
8. Mclaurin, J., Franklin, T., Fraser, P. E., and Chakrabartty, A. (1998) J. Biol. Chem. 273, 4506-4515[Abstract/Free Full Text]
9. Wang, S. S., Rymer, D. L., and Good, T. A. (2001) J. Biol. Chem. 276, 42027-42034[Abstract/Free Full Text]
10. Pyo, H., Joe, E., Jung, S., Lee, S. H., and Jou, I. (1999) J. Biol. Chem. 274, 34589-34594
11. Kanda, N., and Watanabe, S. (2001) J. Immunol. 166, 72-80[Abstract/Free Full Text]
12. Kishimoto, T., Taga, T., and Akira, S. (1994) Cell 76, 253-262[CrossRef][Medline] [Order article via Infotrieve]
13. Igaz, P., Toth, S., and Falus, A. (2001) Inflamm. Res. 50, 435-441[CrossRef][Medline] [Order article via Infotrieve]
14. Kovarik, P., Mangold, M., Ramsauer, K., Heidari, H., Steinborn, R., Zotter, A., Levy, D. E., Muller, M., and Decker, T. (2001) EMBO J. 20, 91-100[CrossRef][Medline] [Order article via Infotrieve]
15. Park, C., and Schindler, C. (1998) Methods 15, 175-188[CrossRef][Medline] [Order article via Infotrieve]
16. Wen, Z., Zhong, Z., and Darnell, J. E. (1995) Cell 82, 241-250[CrossRef][Medline] [Order article via Infotrieve]
17. Streit, W. J., Walter, S. A., and Pennell, N. A. (1999) Prog. Neurobiol. (New York) 57, 563-581
18. Fischer, H., and Reichmann, G. (2001) J. Immunol. 166, 2717-2726[Abstract/Free Full Text]
19. Yang, M. S., Park, E. J., Sohn, S., Kwon, H. S., Shin, W. H., Pyo, H. K., Jin, B., Choi, K. S., Jou, I., and Joe, E. (2002) Glia 38, 273-280[CrossRef][Medline] [Order article via Infotrieve]
20. Xuan, Y.-T., Guo, Y., Han, H., Zhu, Y., and Bolli, R. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 9050-9055[Abstract/Free Full Text]
21. Ehret, G. B., Reichenbach, P., Schindler, U., Horvath, C. M., Fritz, S., Nabholz, M., and Bucher, P. (2001) J. Biol. Chem. 276, 6675-6688[Abstract/Free Full Text]
22. Kovarik, P., Stoiber, D., Novy, M., and Decker, T. (1998) EMBO J. 17, 3660-3668[CrossRef][Medline] [Order article via Infotrieve]
23. Ganster, R. W., Taylor, B. S., Shao, L., and Geller, D. A. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 8638-8643[Abstract/Free Full Text]
24. Gao, J. J., Morrison, D. C., Parmely, T. J., Russell, S. W., and Murphy, W. J. (1997) J. Biol. Chem. 272, 1226-1230[Abstract/Free Full Text]
25. Stark, G. R., Kerr, I. M., Williams, B. R. G., Silvermann, R. H., and Schreiber, R. D. (1998) Annu. Rev. Biochem. 67, 227-264[CrossRef][Medline] [Order article via Infotrieve]
26. Schindler, C. (1999) Exp. Cell Res. 253, 7-14[CrossRef][Medline] [Order article via Infotrieve]
27. O'Shea, J. (1997) Immunity 7, 1-11[Medline] [Order article via Infotrieve]
28. Takaoka, A., Mitani, Y., Suemori, H., Sato, M., Yokochi, T., Noguchi, S., Tanaka, N., and Taniguchi, T. (2000) Science 288, 2357-2360[Abstract/Free Full Text]
29. Tessitore, A., Pastore, L., Rispoli, A., Cilenti, L., Toniato, E., Flati, V., Farina, A. R., Frati, L., Gulino, A., and Martinotti, S. (1998) Eur. J. Biochem. 258, 968-975[Medline] [Order article via Infotrieve]
30. Zhou, Z. H., Chaturvedi, P., Han, Y. L., Aras, S., Li, Y. S., Kolattukudy, P. E., Ping, D., Boss, J. M., and Ransohoff, R. M. (1998) J. Immunol. 160, 3908-3916[Abstract/Free Full Text]
31. Ganster, R. W., and Geller, D. A. (2000) in Nitric Oxide: Biology and Pathobiology (Ignaro, L., ed) , pp. 129-156, Academic, San Diego
32. David, M., Petricoin, E., III, Benjamin, C., Pine, R., Weber, M. J., and Lancer, A. C. (1995) Science 269, 1721-1723[Abstract/Free Full Text]
33. Takaoka, A., Tanaka, N., Mitani, Y., Miyazaki, T., Fujii, H., Sato, M., Kovarik, P., Decker, T., Schlessinger, J., and Taniguchi, T. (1999) EMBO J. 18, 2480-2488[CrossRef][Medline] [Order article via Infotrieve]
34. Gouni-Berthold, I., Seul, C., Ko, Y., Hescheler, J., and Sachinidis, A. (2001) Hypertension 38, 1030-1037[Abstract/Free Full Text]
35. Dreyfus, H., Guerold, B., Freysz, L., and Hicks, D. (1997) Anal. Biochem. 249, 67-78[CrossRef][Medline] [Order article via Infotrieve]
36. Saito, M., Sugano, K., and Nagai, Y. (1979) J. Biol. Chem. 254, 7845-7854[Abstract/Free Full Text]
37. Kielczynski, W., Harrison, L. C., and Leedman, P. J. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 1991-1995[Abstract/Free Full Text]
38. Hakomori, S. (1990) J. Biol. Chem. 265, 18713-18716[Abstract/Free Full Text]
39. Kassahara, K., Watanabe, Y., Yamamoto, T., and Sanai, Y. (1997) J. Biol. Chem. 272, 29947-29953[Abstract/Free Full Text]
40. Fu, X.-Y., Kessler, D. S., Veals, S. A., Levy, D. E., and Darnelle, J. E. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 8555-8559[Abstract/Free Full Text]
41. Kessler, D. S., Veaks, S. A., Fu, X. Y., and Leavy, D. E. (1990) Genes Dev. 4, 1753-1765[Abstract/Free Full Text]
42. Darnelle, J. E. (1997) Science 277, 1630-1635[Abstract/Free Full Text]
43. Nelms, K., Keegan, A. D., Zamorano, J., Ryan, J. J., and Paul, W. E. (1999) Annu. Rev. Immunol. 17, 701-738[CrossRef][Medline] [Order article via Infotrieve]
44. Jiang, H., Harris, M. B., and Rothman, P. (2000) J. Allergy Clin. Immunol. 105, 1063-1070[CrossRef][Medline] [Order article via Infotrieve]
45. Johnston, J. A., Kawamura, M., Kirken, R. A., Chen, Y. Q., Blake, T. B., Shibuya, K., Orhaldo, J. R., McVicar, D. W., and O'Shea, J. J. (1994) Nature 370, 151-153[CrossRef][Medline] [Order article via Infotrieve]
46. Bacon, C. M., McVicar, D. W., Ortaldo, J. R., Rees, R. C., O'Shea, J. J., and Johnston, J. A. (1995) J. Exp. Med. 181, 1425-1431[Abstract/Free Full Text]
47. Imada, K., and Leonard, W. J. (2000) Mol. Immunol. 37, 1-11[CrossRef][Medline] [Order article via Infotrieve]
48. Wang, W., Fuhrer, D., Marshall, M., and Yang, Y. (1995) J. Biol. Chem. 270, 27999-28002[Abstract/Free Full Text]
49. Laskin, D. L., and Pendino, K. J. (1995) Annu. Rev. Pharmacol. Toxicol. 35, 655-677[CrossRef][Medline] [Order article via Infotrieve]
50. Bhat, N. R., Zhang, P., Lee, J. C., and Hogan, E. L. (1998) J. Neurosci. 18, 1633-1641[Abstract/Free Full Text]
51. Kopitz, J., von Retzenstein, C., Burchet, M., Cantz, M., and Gabius, H. (1998) J. Biol. Chem. 273, 11205-11211[Abstract/Free Full Text]
52. Garofalo, T., Sorice, M., Misasi, R., Cinques, B., Giammatteo, M., Pontieri, G. M., Cifone, M. G., and Pavan, A. (1998) J. Biol. Chem. 273, 35153-35160[Abstract/Free Full Text]
53. Gouy, H., Deterre, P., Debre, P., and Bismuth, G. (1994) J. Immunol. 152, 3271-3281[Abstract]
54. Meuillet, E., Cremel, G., Drefus, H., and Hicks, D. (1996) Glia 17, 206-216[CrossRef][Medline] [Order article via Infotrieve]
55. Mitsuda, T., Furukawa, K., Miyazaki, H., Urano, T., and Furukawa, K. (2002) J. Biol. Chem. 29, 11239-11246
56. Hader, T., and Simons, K. (1999) Eur. J. Immunol. 29, 556-562[CrossRef][Medline] [Order article via Infotrieve]
57. Kantakamalakul, W., Politis, A. D., Marecki, S., Sullivan, T., Ozato, K., Fenton, M. J., and Vogel, S. N. (1999) J. Immunol. 162, 7417-7425[Abstract/Free Full Text]
58. Simons, K., and Toomre, D. (2000) Nat. Rev. Mol. Cell. Biol. 1, 31-39[CrossRef][Medline] [Order article via Infotrieve]
59. Iwabuchi, K., Yamamura, S., Primetti, A., Handa, K., and Hakomori, S. (1998) J. Biol. Chem. 273, 9130-9138[Abstract/Free Full Text]
60. Prinetti, A., Iwabuchi, K., and Hakomori, S. (1999) J. Biol. Chem. 274, 20916-20924[Abstract/Free Full Text]
61. Danial, N., Pernis, A., and Rothmann, P. (1995) Science 269, 1875-1877[Abstract/Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
H. J. Yoon, S.-B. Jeon, I.-H. Kim, and E. J. Park
Regulation of TLR2 Expression by Prostaglandins in Brain Glia
J. Immunol., June 15, 2008; 180(12): 8400 - 8409.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
N. Yang, M. Luo, R. Li, Y. Huang, R. Zhang, Q. Wu, F. Wang, Y. Li, and X. Yu
Blockage of JAK/STAT signalling attenuates renal ischaemia-reperfusion injury in rats
Nephrol. Dial. Transplant., January 1, 2008; 23(1): 91 - 100.
[Abstract] [Full Text] [PDF]